세계의 헬리코박터 파일로리 비침습 검사 시장 : 검사 유형별, 방법별, 최종 용도별 - 예측(2024-2032년)

Global Non-invasive Helicobacter Pylori Testing Market will infer over 7.1% CAGR between 2024 and 2032, ushered by the rising incidences of H. pylori infections. An NCBI study revealed a 44.3% prevalence of H. pylori infection. In developing nations, the rate stands at 50.8%, higher than the 34.7% observed in developed countries. Men exhibit a predominant infection rate of 46.3% compared to 42.7% in women. Among adults >=18 years, the infection rate is significantly higher at 48.6%, while children show a lower rate of 32.6%.

The integration of non-invasive Helicobacter pylori testing methods into routine healthcare practices is directed by their proven efficiency in diagnosing H. pylori infections without invasive procedures, which aligns with healthcare providers goals of improving patient comfort and reducing procedural risks.

As non-invasive helicobacter pylori tests are accessible and widely accepted, healthcare facilities are incorporating them into their standard diagnostic protocols. This trend improves patient care by enabling timely and accurate diagnosis and boosts demand for non-invasive testing solutions, indicating a broader shift towards efficient and patient-centered healthcare practices.

The overall non-invasive helicobacter pylori testing industry is segmented based on test type, method, end-use, and region.

The urea breath test segment will grab a substantial non-invasive helicobacter pylorus testing market share by 2032 due to its effectiveness in diagnosing H. pylori infections without invasive procedures. This test detects the presence of H. pylori bacteria by measuring carbon dioxide levels in breath samples, offering a convenient and reliable alternative to endoscopic methods. As healthcare providers prioritize patient comfort and cost-efficiency, the urea breath test stands out for its simplicity and accuracy, driving its adoption in clinical settings and contributing to the overall growth of the non-invasive testing market.

The Point-of-Care POC test segment will register a noteworthy CAGR in the non-invasive helicobacter pylori testing market between 2024 and 2032. The Point-of-Care POC test segment is increasing because of its rapid and convenient diagnostic capabilities. POC tests enable healthcare providers to obtain quick results at the patients bedside or in outpatient settings, facilitating timely treatment decisions. This approach is particularly beneficial in reducing turnaround times and improving patient outcomes by swiftly identifying H. pylori infections. As healthcare facilities strive for efficient diagnostic solutions that enhance workflow and patient satisfaction, the adoption of non-invasive POC tests continues to grow, underscoring their pivotal role in modern clinical practice.

Asia Pacific non-invasive helicobacter pylori testing market size will exhibit a noteworthy CAGR during the forecast period. Increasing healthcare access and awareness programs about gastrointestinal health have heightened the need for efficient diagnostic solutions. Non-invasive tests are preferred in this region for their affordability and patient comfort, aligning with cultural preferences for minimally invasive procedures. Additionally, the high prevalence of H. pylori infections in Asia Pacific underscores the urgency for accurate and accessible testing methods. As healthcare infrastructure continues to improve and diagnostic technologies advance, the adoption of non-invasive testing for H. pylori will expand.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of gastric and duodenal illnesses
    • 3.2.1.2 Increasing need for effective anti-microbial treatments
    • 3.2.1.3 Advancements in laboratory serological assay
    • 3.2.1.4 Growing demand for point-of-care testing devices
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Strict regulatory regulations and the low detection rate of H. pylori infection
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Reimbursement scenario
• 3.6 Technological landscape
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Serologic test
• 5.3 Urea breath test
• 5.4 Stool/fecal antigen test

Chapter 6 Market Estimates and Forecast, By Method, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Laboratory based test
• 6.3 Point of care (POC) test

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Clinics
• 7.4 Diagnostic laboratories
• 7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott
• 9.2 Biohit Oyj
• 9.3 Bio-Rad Laboratories, Inc.
• 9.4 Cardinal Health
• 9.5 certest Biotech srl
• 9.6 Fisher Scientific
• 9.7 Gulf Coast Scientific
• 9.8 Meridian Bioscience Inc.
• 9.9 Quidel Corporation
• 9.10 Tri-Med